Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine Relapse Prevention in GAD
NCT00122863Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2005
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Duloxetine with Placebo (2 arms). Primary endpoint: Time to Relapse of Anxiety Symptoms at 26 weeks. Started Jan 2005; status: completed.
02
Drugs
duloxetine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00122863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00122863.